• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Quoin Pharmaceuticals Ltd.

    2/14/25 4:54:47 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care
    Get the next $QNRX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Quoin Pharmaceuticals, Ltd.

    (Name of Issuer)


    American Depositary Shares, each representing one (1) Ordinary Shares, no par value per share QNRX The Nasdaq Stock Market LLC Ordinary S

    (Title of Class of Securities)


    74907L300

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    74907L300


    1Names of Reporting Persons

    Armistice Capital, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    934,312.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    934,312.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    934,312.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    IA, OO


    SCHEDULE 13G

    CUSIP No.
    74907L300


    1Names of Reporting Persons

    Steven Boyd
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    934,312.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    934,312.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    934,312.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Quoin Pharmaceuticals, Ltd.
    (b)Address of issuer's principal executive offices:

    42127 Pleasant Forest Court, Ashburn, VA 20148-7349
    Item 2. 
    (a)Name of person filing:

    Armistice Capital, LLC Steven Boyd Collectively, the "Reporting Persons"
    (b)Address or principal business office or, if none, residence:

    Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America Steven Boyd c/o Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America
    (c)Citizenship:

    Armistice Capital, LLC - Delaware; Steven Boyd - United States of America
    (d)Title of class of securities:

    American Depositary Shares, each representing one (1) Ordinary Shares, no par value per share QNRX The Nasdaq Stock Market LLC Ordinary S
    (e)CUSIP No.:

    74907L300
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    934,312
    (b)Percent of class:

    9.99  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    934,312

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    934,312 The percentage of Shares reported to be beneficially owned by the Reporting Persons are based on information from the Issuer. Armistice Capital, LLC ("Armistice Capital") is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Armistice Capital, LLC
     
    Signature:/s/ Steven Boyd
    Name/Title:Steven Boyd - Managing Member
    Date:02/14/2025
     
    Steven Boyd
     
    Signature:/s/ Steven Boyd
    Name/Title:Steven Boyd
    Date:02/14/2025
    Exhibit Information

    JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: February 14, 2025 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

    Get the next $QNRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QNRX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $QNRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome

    Confirmation Received from MHLW That QRX003 Qualifies for Both Orphan Drug Designation and Fast Track Regulatory Review Status Quoin Initiating the Establishment of a Japanese Subsidiary to Facilitate Self-Commercialization of QRX003 in Japan, if Approved Orphan Drug Designation Previously Granted by Both the U.S. Food and Drug Administration (FDA) and the European Medicines (EMA) Agency in 2025 ASHBURN, Va., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that following a successful meeting with the Japanese MHLW that it has

    1/27/26 8:30:00 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome

    QRX003 could become the first ever approved treatment for Netherton Syndrome ASHBURN, Va., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has filed an application for Breakthrough Medicine Designation with the Saudi Food and Drug Authority (SFDA) for QRX003, its lead investigational, late-stage topical product candidate for the treatment of Netherton Syndrome. The SFDA's Breakthrough Medicine Designation program is designed to expedite the development, review, and potential availability of medicines that address seriou

    1/20/26 8:30:00 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies

    Target Loadings of 4% and 5% Rapamycin Achieved for Topical Lotion and Dermal Patch Delivery Technologies Respectively Clinical Trial and Stability Batch Manufacture to Commence in Q4 2025 Clinical Testing in a Number of Indications Including Microcystic Lymphatic Malformations and Venous Malformations, among others to Commence 1H 2026      ASHBURN, Va., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the target loading concentrations for its two topical rapamycin delivery technologies have been successfully achieved. Spe

    11/11/25 8:30:00 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    $QNRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Lawlor Sally Bridget

    4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

    2/6/26 5:24:03 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Cooper Joseph Patrick

    4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

    2/6/26 5:21:52 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Culverwell Anthony James

    4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

    2/6/26 5:20:19 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    $QNRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Langer Dennis bought $128,640 worth of ADSs (15,152 units at $8.49), increasing direct ownership by 1,515,200% to 15,153 units (SEC Form 4)

    4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

    10/15/25 5:15:20 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Chief Operating Officer Carter Denise P. bought $250,000 worth of Ordinary Shares (555,556 units at $0.45), increasing direct ownership by 1,180% to 602,648 units (SEC Form 4)

    4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

    12/27/24 5:17:23 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Myers Michael bought $250,000 worth of Ordinary Shares (555,556 units at $0.45), increasing direct ownership by 1,176% to 602,808 units (SEC Form 4)

    4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

    12/27/24 5:16:51 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    $QNRX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Quoin Pharmaceuticals Ltd.

    SCHEDULE 13G/A - Quoin Pharmaceuticals, Ltd. (0001671502) (Subject)

    2/11/26 5:10:41 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Quoin Pharmaceuticals Ltd.

    SCHEDULE 13G/A - Quoin Pharmaceuticals, Ltd. (0001671502) (Subject)

    2/2/26 8:01:42 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Quoin Pharmaceuticals Ltd. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)

    1/20/26 5:18:14 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    $QNRX
    Financials

    Live finance-specific insights

    View All

    Quoin Pharmaceuticals Announces Second Quarter 2025 Financial Results and Corporate Update

    -  Positive 6 Month Clinical Data Reported for Ongoing Pediatric Netherton Syndrome Study -  FDA Clears Second Pivotal Study of QRX003 for Netherton Syndrome -  Initial Positive Data Announced from Peeling Skin Syndrome Pediatric Study -  Orphan Drug Designation Granted by European Medicines Agency for QRX003 -  Rare Pediatric Disease Designation Awarded by U.S. FDA -  NETHERTON NOW Campaign Expanded with New Patient and Expert Video Releases ASHBURN, Va., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases provided a corporate upda

    8/7/25 8:30:00 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial Results

    Continued Progress in Ongoing Late-Stage Netherton Syndrome Studies Announced Positive Clinical Data for Adult and Pediatric Netherton Patients Provided Clear Visual Evidence of QRX003 Mechanism of Action Patent Portfolio Expanded to Support Pipeline GrowthLaunch of NETHERTON NOW Advocacy Initiative ASHBURN, Va., May 13, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a late clinical-stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today provides a business update and announces financial results for the quarter ended March 31, 2025. Quoin CEO Dr. Michael Myers

    5/13/25 8:00:00 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results

    Quoin Initiates Peeling Skin Syndrome Clinical Program Further Expansion of International Reach for Netherton Syndrome Clinical Trials Significant Insider Share Purchases by the Entire Management Team ASHBURN, Va., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a clinical-stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today provides a business update and announces financial results for the three and nine months ended Sept. 30, 2024. Quoin CEO Dr. Michael Myers said, "The third quarter has been marked by notable achievements, including expanding the c

    11/7/24 8:00:00 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    $QNRX
    Leadership Updates

    Live Leadership Updates

    View All

    Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy

    ASHBURN, Va., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the appointment of its new Chief Financial Officer as the Company advances its lead product candidate, QRX003, through pivotal clinical studies and prepares for potential commercialization. Quoin has appointed Sally Lawlor, BCL, FCA, as its new Chief Financial Officer, effective immediately. Ms. Lawlor is an accomplished finance executive with over 20 years of experience in financial leadership roles in public and private companies as well as a Big Four accounting fir

    8/18/25 8:30:00 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    $QNRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Quoin Pharmaceuticals Ltd.

    SC 13G/A - Quoin Pharmaceuticals, Ltd. (0001671502) (Subject)

    11/14/24 7:23:29 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Quoin Pharmaceuticals Ltd. (Amendment)

    SC 13G/A - Quoin Pharmaceuticals, Ltd. (0001671502) (Subject)

    2/13/24 8:11:42 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Quoin Pharmaceuticals Ltd. (Amendment)

    SC 13G/A - Quoin Pharmaceuticals, Ltd. (0001671502) (Subject)

    2/14/23 2:40:46 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care